Mesothelioma immunotherapy trial involves targeted radiotherapy

Memorial Sloan Kettering Cancer Centre in New York City has opened a clinical trial for mesothelioma involving a combination of targeted radiotherapy and the novel immunotherapy drug avelumab. “The combination of radiotherapy treatment and immunotherapy may be more effective against cancer than either radiotherapy or immunotherapy alone,” reads the trial description on